Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
A booming gray market is turning kitchens into makeshift pharmacies as Americans chase cheaper alternatives to high-priced obesity drugs. High prices and limited insurance coverage have driven a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results